4DMedical has attracted more than $100 million (AU$150 million) in new funding, which will be used to accelerate U.S. adoption of its CT:VQ product and expand research and development efforts, strengthening its leadership in software-based lung imaging technology.

CT:VQ is 4DMedical’s U.S. Food and Drug Administration (FDA)-cleared, SaaS (Software-as-a-Service) technology that provides ventilation and perfusion insights from computed tomography (CT) imaging. Within just four months of FDA clearance, CT:VQ was deployed by four elite U.S. academic medical centers: Stanford, Cleveland Clinic, University of Miami, and UC San Diego Health. These adoptions reflect growing interest from clinicians seeking quantified, actionable, and functional information not available from traditional imaging but increasingly vital to support diagnosis, treatment planning, and longitudinal monitoring.

“This is an extraordinarily important and validating event for multiple reasons,” 4DMedical Founder/CEO Andreas Fouras, Ph.D., said. “First, it reflects growing global recognition of the technological leadership of 4DMedical, including our products such as CT:VQ. And it recognizes both the commercial progress and even greater growth potential we have in the U.S. With this institutional backing and a strengthened balance sheet, we will scale adoption, accelerate R&D, deepen partnerships, and dominate the global marketplace for software-based lung imaging tools.”

4DMedical intends to use the funding to expand CT:VQ’s availability in the United States and support health systems with implementation at scale, including:

• Commercial expansion across U.S. academic medical centers and health systems, with a focus on real-world adoption and multidisciplinary use
• Customer success, training, and technical support to help integrate CT:VQ into existing clinical workflows and drive consistent utilization
• Ongoing research and development to expand 4DMedical’s technology leadership, product portfolio, and capabilities in functional lung imaging
• Operational scale and flexibility to support additional growth opportunities and sustained clinical partnerships

After securing the funding, 4DMedical reported a pro forma cash position exceeding $130 million (AU$200+ million), which will support the company’s U.S. expansion strategy and growing installed base.

4DMedical’s products are delivered through a Software-as-a-Service model designed to integrate with existing hospital infrastructure. The company also highlighted strategic partnerships, including with Philips, aimed at supporting broader adoption pathways.

4DMedical Limited is a global medical technology company that creates and deploys advanced software-based cardiothoracic imaging technology that integrates both proprietary algorithms and artificial intelligence. 4DMedical’s software platform delivers deep, quantitative insights from routine clinical imaging to help clinicians assess lung function and cardiopulmonary disease with significantly greater precision.

These insights help pulmonologists, radiologists, and hospital teams quantify regional lung function, support diagnosis and disease monitoring, and inform treatment and surgical planning. 4DMedical’s solutions are designed to integrate into existing clinical workflows. They provide actionable, patient-specific information that supports better decision-making and operational efficiency across a range of respiratory conditions.